Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtriCure, Inc. (ATRC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. AtriCure is a Nasdaq Global Market registrant whose common stock is listed under the symbol ATRC, and its filings offer detailed information on financial performance, capital structure, and material corporate events.
Investors can review Form 8-K current reports in which AtriCure discloses items such as preliminary and quarterly financial results, amendments to its Credit Agreement, and the creation of direct financial obligations. For example, recent 8-K filings describe an amendment to the company’s asset-based revolving credit facility with JPMorgan Chase Bank, N.A., including an extension of the term, a reduction in the overall interest rate, and changes to certain covenants. Other 8-Ks furnish press releases detailing revenue by product category and geography, non-GAAP metrics like adjusted EBITDA and adjusted loss per share, and commentary on operating trends.
Through its periodic reports and related exhibits, AtriCure outlines balance sheet data, income statement details, and non-GAAP reconciliations. These materials help readers understand how the company reports revenue from open ablation, minimally invasive ablation, pain management, and appendage management, as well as its research and development and selling, general, and administrative expenses. The filings also describe the structure and collateral of the ABL Facility, including the security interest in the assets of the borrowers and guarantees by material domestic subsidiaries.
On this page, Stock Titan enhances access to AtriCure’s filings with AI-powered summaries that explain the key points of lengthy documents such as 8-Ks and, when available, 10-Q and 10-K reports. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly, while AI-generated highlights can help users quickly identify important changes in credit agreements, financial guidance, or operating results without reading every line of the original filing.
For those tracking ATRC, this filings hub is a central resource for analyzing the company’s disclosed financial condition, capital arrangements, and significant events as reported in its official SEC documents.
AtriCure, Inc. is asking stockholders to approve several items at its virtual 2026 annual meeting, including amendments to expand its equity compensation plans. The company seeks to add 1,500,000 shares to the 2023 Stock Incentive Plan and 750,000 shares to the 2018 Employee Stock Purchase Plan.
Stockholders are also being asked to elect nine directors for one-year terms, ratify Deloitte & Touche LLP as independent auditor for 2026, and approve an advisory "say-on-pay" vote on named executive officer compensation. The meeting will be held online on May 18, 2026; holders of AtriCure common stock as of March 26, 2026, when 50,634,808 shares were outstanding, are entitled to vote.
AtriCure Inc Schedule 13G/A Amendment No. 6: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0%. The filing notes an internal realignment on January 12, 2026 that disaggregated reporting by Vanguard subsidiaries. The amendment is signed by Ashley Grim on 03/26/2026.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported an open-market sale of 5,000 shares of common stock. The shares were sold at a weighted average price of $29.83 per share, in multiple trades executed between $29.79 and $29.92. Following this transaction, he directly holds 96,875 shares of AtriCure common stock.
ATRC submitted a Form 144 notice reporting proposed sales of common stock awards. The filing lists Performance Shares: 1,561 with an award date of 03/01/2024 and three Restricted Stock items of 813, 1,578, and 1,048 shares with award dates of 03/01/2023 and 03/01/2024.
The securities are identified as being sold by the Issuer and are reported for sale under Rule 144; timing and cash‑flow treatment are not stated in the excerpt.
AtriCure, Inc. director Robert S. White exercised non-qualified stock options for 10,000 shares at $14.99 per share. These options were originally granted on May 25, 2016 and vested over four years. Following the exercise, he directly holds 122,174 shares of AtriCure common stock.
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported bona fide gifts totaling 6,000 shares of AtriCure common stock on March 6, 2026, consisting of separate transfers of 5,000 shares and 1,000 shares. No consideration was received for these gifts to his children and sibling, and his directly owned stake was reported as 778,498 shares following the gifts. He also reported indirect holdings held by his children, parents, and sibling, and disclaimed beneficial ownership of those indirect holdings except for his pecuniary interest.
AtriCure, Inc. President and CEO Michael H. Carrel reported equity compensation and related tax withholding transactions in AtriCure common stock. On March 1, 2026, he acquired 68,618 shares through a restricted stock award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date.
He also acquired 101,280 shares upon the vesting and release of a performance share award under the same 2023 plan, after the company performance goals and required service period were met. To cover tax withholding obligations from vesting awards, he transferred 72,777 shares back to the company at $31.26 per share, characterized as a tax-withholding disposition. After these direct transactions, he directly held 784,498 shares of common stock.
In addition, Form 4 reflects 9,310 shares held indirectly by his children and 2,250 shares held indirectly by his parents. A footnote states he disclaims beneficial ownership of these indirectly held securities, except to the extent of his pecuniary interest.
AtriCure, Inc. Chief Marketing & Strategy Officer Justin J. Noznesky reported equity compensation and related tax withholding in company stock. He acquired 27,991 shares through a new restricted stock award and 15,198 shares from a performance share award that vested after meeting company performance and service requirements. To cover tax obligations on vested awards, he transferred 15,586 shares back to the company at a price of $31.26 per share, leaving him with 106,401 shares of common stock held directly.
AtriCure, Inc. Chief Technical Officer Salvatore Privitera reported equity compensation activity involving company common stock. He acquired 30,390 shares on March 1, 2026 through a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares on the same date from the vesting and release of a Performance Share Award under the same plan after company performance goals and service requirements were met. To cover tax withholding obligations related to vesting and release of prior awards, he transferred 13,127 shares back to the company at $31.26 per share, and directly owned 158,048 shares after these transactions.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported equity awards and related tax withholding transactions in company common stock. He acquired 30,390 shares through a restricted stock award under the 2023 Stock Incentive Plan, with one third vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares from the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from earlier restricted or performance share vesting, he transferred 15,585 shares back to AtriCure at a price of $31.26 per share.